Exelixis (EXEL) has come back into focus after being removed from several Russell 1000 defensive style indices. This shift may influence how some quantitative and index-linked investors treat the stock.

Beyond the index changes, Exelixis has seen firm buying interest, with a 27.28% 3 month share price return and a 28.16% year to date share price return at a last close of US$55.85. The 5 year total shareholder return of 210.11% reflects how the long term story has evolved.

If Exelixis has you looking more broadly at oncology and next generation treatment themes, it may be worth scanning for other potential opportunities via the 40 healthcare AI stocks

So, with Exelixis posting strong recent returns yet trading at what some models suggest is a steep intrinsic discount of 76%, is the stock still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 12.5% Overvalued

At a last close of US$55.85, Exelixis sits above the narrative fair value estimate of about US$49.65, which frames how some investors view its current pricing.

The recent introduction and rapid uptake of CABOMETYX in neuroendocrine tumors, combined with its continued strength and market leadership in renal cell carcinoma, signals an expanding patient base in tumor types with high unmet need. This is described as being poised to drive strong durable revenue growth as aging populations and rising cancer incidence increase long-term demand for oncology therapeutics.

Curious what underpins that fair value call? The narrative focuses on steadily rising revenues, firm profit margins, and a lower future earnings multiple than many peers. The exact mix of growth, profitability, and discount rate assumptions is where the story becomes more detailed.

Result: Fair Value of $49.65 (OVERVALUED)

However, the Exelixis story still leans heavily on CABOMETYX concentration and ongoing margin pressure from discounted 340B volumes, either of which could quickly challenge this fair value narrative.

Another View: Exelixis Through the P/E Lens

While the narrative fair value points to Exelixis as about 12.5% overvalued at US$55.85, the simple earnings multiple sends a different signal. The stock trades on a P/E of 16.8x, below both peers at 25.8x and the US Biotechs industry at 17.3x, and below an estimated fair ratio of 20.7x. That gap suggests the market may be assigning either a margin of safety or a risk discount, so which side do you think it is?

For a closer look at how this earnings based view stacks up against other approaches, including how the fair ratio could shift over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Exelixis presenting a mix of strong recent returns and contrasting valuation signals, it makes sense to move quickly and test the story against your own expectations. To weigh up both the concerns and the potential upside in one place, review the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Exelixis?

If Exelixis has sharpened your focus on finding better opportunities, do not stop here. Use curated stock lists to pressure test your next move and avoid missing timely ideas.

• Zero in on potential mispricings by scanning companies flagged as 44 high quality undervalued stocks that combine stronger fundamentals with pricing that models suggest may lag underlying quality.
• Strengthen your income stream by reviewing 7 dividend fortresses that offer higher yields while still aiming to keep balance sheets and cash flows in reasonable shape.
• Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems where solid financial metrics have yet to attract broad market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.